Hidetaka Kawabata
Overview
Explore the profile of Hidetaka Kawabata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kawaguchi S, Kinowaki K, Tamura N, Nishikawa A, Shibata A, Tanaka K, et al.
Medicine (Baltimore)
. 2022 Dec;
101(50):e32199.
PMID: 36550858
Background: Solitary fibrous tumors (SFT) are uncommon mesenchymal neoplasms which can arise in any anatomical location. Pleural SFTs have been most frequently documented; however, breast SFT is an exceedingly rare...
12.
Horie K, Takagi K, Takeiwa T, Mitobe Y, Kawabata H, Suzuki T, et al.
Cells
. 2022 Nov;
11(22).
PMID: 36429038
Recent advances in RNA studies have revealed that functional long noncoding RNAs (lncRNAs) contribute to the biology of cancers. In breast cancer, estrogen receptor α (ERα) is an essential transcription...
13.
Kawaguchi S, Tamura N, Tanaka K, Kobayashi Y, Sato J, Kinowaki K, et al.
Front Oncol
. 2022 Sep;
12:989650.
PMID: 36176414
Purpose: Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) are useful for detecting axillary lymph node (ALN) metastasis in invasive ductal breast cancer (IDC); however, there is limited...
14.
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, et al.
Data Brief
. 2022 Sep;
45:108558.
PMID: 36118297
The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues...
15.
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, et al.
Eur J Cancer
. 2022 Jun;
171:193-202.
PMID: 35728379
Background: Preclinical models revealed potential synergistic effects of programmed cell death-1 inhibitors and anti-vascular endothelial growth factor (VEGF) antibodies. Therefore, we investigated the use of nivolumab, bevacizumab, and paclitaxel triple...
16.
Takeiwa T, Ikeda K, Suzuki T, Sato W, Iino K, Mitobe Y, et al.
Sci Rep
. 2022 Jun;
12(1):9495.
PMID: 35681031
Breast cancer is the most common cancer type among women worldwide. The majority of breast cancer expresses estrogen receptor (ER) and endocrine therapy is a standard treatment of ER-positive breast...
17.
Ogura T, Azuma K, Takeiwa T, Sato J, Kinowaki K, Ikeda K, et al.
Pathol Int
. 2022 Feb;
72(2):96-106.
PMID: 35174936
Tripartite motif (TRIM) family proteins are involved in various biological processes and the pathophysiology of cancers. However, the roles of TRIM39, a TRIM family member, in breast cancer is not...
18.
Ogura T, Azuma K, Sato J, Kinowaki K, Takayama K, Takeiwa T, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34768935
Octamer transcription factor 1 (OCT1) is a transcriptional factor reported to be a poor prognostic factor in various cancers. However, the clinical value of OCT1 in breast cancer is not...
19.
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, et al.
Breast Cancer Res Treat
. 2021 Sep;
190(3):425-434.
PMID: 34554370
Purpose: The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential...
20.
Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai S, et al.
Breast Cancer Res Treat
. 2021 Mar;
188(1):117-131.
PMID: 33763789
Purpose: To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Methods: Patients in group A (aged < 65 years with homologous recombination deficiency, HRD, score ...